R Caswell-Smith1,2, A Hosking1,3, T Cripps1, C Holweg4, J Matthews4, M Holliday1, C Maillot1, J Fingleton1, M Weatherall1,5, I Braithwaite1,2,6, R Beasley7,8,9. 1. Medical Research Institute of New Zealand, Wellington, New Zealand. 2. Victoria University of Wellington, Wellington, New Zealand. 3. University of Auckland, Auckland, New Zealand. 4. Genentech Inc, San Francisco, CA, USA. 5. University of Otago, Wellington, New Zealand. 6. Capital & Coast District Health Board, Wellington, New Zealand. 7. Medical Research Institute of New Zealand, Wellington, New Zealand. richard.beasley@mrinz.ac.nz. 8. Victoria University of Wellington, Wellington, New Zealand. richard.beasley@mrinz.ac.nz. 9. Capital & Coast District Health Board, Wellington, New Zealand. richard.beasley@mrinz.ac.nz.
Abstract
BACKGROUND: The clinical utility of serum periostin as a type 2 biomarker in asthma is limited by lack of reference range values derived from a population without respiratory disease. OBJECTIVE: To derive age- and sex-related reference intervals for serum periostin from an adult population without asthma or COPD. METHODS: Serum periostin levels were measured in 480 individuals, comprising 60 female and 60 male adults in each of the 18- to 30-year, 31- to 45-year, 46- to 60-year and 61- to 75-year age groups. Key exclusion criteria included a doctor's diagnosis of asthma, chronic bronchitis or COPD, and a history of wheezing or use of respiratory inhalers in the last 12 months. The distribution of periostin and logarithm-transformed periostin levels was derived, and 90% confidence intervals for an individual prediction were calculated. RESULTS: The distribution of serum periostin was right skewed with a mean (SD) periostin of 51.2 (11.9) ng/mL, median (IQR) 50.1 (43.1 to 56.9) ng/mL and range 28.1 to 136.4 ng/mL. There was no association between logarithm periostin and age or sex, although levels were low in current smokers. The 90% confidence limits for periostin were 35.0 and 71.1 ng/mL. CONCLUSIONS AND CLINICAL RELEVANCE: Serum periostin levels in adults without asthma or COPD are similar to those in adults with asthma. Serum periostin measurements do not need to be adjusted to take account of a patient's age or sex, although levels are lower in current smokers. Reference values for serum periostin levels in adults without asthma or COPD are provided.
BACKGROUND: The clinical utility of serum periostin as a type 2 biomarker in asthma is limited by lack of reference range values derived from a population without respiratory disease. OBJECTIVE: To derive age- and sex-related reference intervals for serum periostin from an adult population without asthma or COPD. METHODS: Serum periostin levels were measured in 480 individuals, comprising 60 female and 60 male adults in each of the 18- to 30-year, 31- to 45-year, 46- to 60-year and 61- to 75-year age groups. Key exclusion criteria included a doctor's diagnosis of asthma, chronic bronchitis or COPD, and a history of wheezing or use of respiratory inhalers in the last 12 months. The distribution of periostin and logarithm-transformed periostin levels was derived, and 90% confidence intervals for an individual prediction were calculated. RESULTS: The distribution of serum periostin was right skewed with a mean (SD) periostin of 51.2 (11.9) ng/mL, median (IQR) 50.1 (43.1 to 56.9) ng/mL and range 28.1 to 136.4 ng/mL. There was no association between logarithm periostin and age or sex, although levels were low in current smokers. The 90% confidence limits for periostin were 35.0 and 71.1 ng/mL. CONCLUSIONS AND CLINICAL RELEVANCE: Serum periostin levels in adults without asthma or COPD are similar to those in adults with asthma. Serum periostin measurements do not need to be adjusted to take account of a patient's age or sex, although levels are lower in current smokers. Reference values for serum periostin levels in adults without asthma or COPD are provided.
Authors: Makiko Nanishi; Michimasa Fujiogi; Robert J Freishtat; Claire E Hoptay; Cindy S Bauer; Michelle D Stevenson; Carlos A Camargo; Kohei Hasegawa Journal: Allergy Date: 2022-01-17 Impact factor: 14.710
Authors: O A Carpaij; F O W Muntinghe; M B Wagenaar; J W Habing; W Timens; H A M Kerstjens; M C Nawijn; L I Z Kunz; P S Hiemstra; G W Tew; C T J Holweg; C A Brandsma; M van den Berge Journal: Respir Res Date: 2018-06-07
Authors: Amali E Samarasinghe; Rhiannon R Penkert; Julia L Hurwitz; Robert E Sealy; Kim S LeMessurier; Catherine Hammond; Patricia J Dubin; D Betty Lew Journal: Biomedicines Date: 2020-10-06
Authors: Rennie L Rhee; Cecile T J Holweg; Kit Wong; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Peter A Merkel Journal: PLoS One Date: 2018-10-11 Impact factor: 3.240